Literature DB >> 9301633

Coagulation factor VII and the risk of coronary heart disease in healthy men.

R Junker1, J Heinrich, H Schulte, J van de Loo, G Assmann.   

Abstract

Numerous investigations have demonstrated the role of thrombus formation in the pathogenesis of coronary heart disease (CHD). A tendency to thrombosis may also be indicated by elevated levels of coagulation factor VII clotting activity (FVIIc). Significant associations of FVIIc with increased coronary risk, however, have been found only in the Northwick Park Heart Study. Here we present the results of the 8-year follow-up of FVIIc measurements in 2780 healthy men of the Prospective Cardiovascular Münster study. In the study population (age at entry, 49.3 +/- 6.1 years, mean +/- SD), 130 CHD events occurred during follow-up. FVIIc was significantly higher in subjects with coronary events than in those without (112.4 +/- 20.1% vs 108.7 +/- 21.4%, P = .023). Compared with individuals without coronary events, FVIIc was not significantly higher in men with nonfatal events (111.7 +/- 20.4%; P = .196, n = 93), but there was a tendency toward higher FVIIc activity in subjects with fatal events (114.6 +/- 19.5%; P = .076, n = 37). In the multiple logistic regression analysis, we did not find FVIIc to be an independent risk factor for CHD, and the significance of FVIIc disappeared after total cholesterol, LDL-cholesterol, and triglycerides were taken into account. The increase in the number of CHD events through higher levels of FVIIc was more pronounced in the presence of additional cardiovascular risk factors: smoking; myocardial infarction events in family; angina pectoris; high levels of fibrinogen, total cholesterol, LDL cholesterol, and triglycerides; and a low level of HDL cholesterol. We conclude that FVIIc is a risk factor for CHD, especially in the presence of additional risk factors, and must be taken into account when assessing cardiovascular risk in men.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301633     DOI: 10.1161/01.atv.17.8.1539

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  17 in total

1.  The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment.

Authors:  J M Walenga; D Hoppensteadt; R Pifarré; N L Fox; S Forman; D B Hunninghake; L Campeau; J A Herd; B J Hoogwerf; A Hickey; J L Probstfield; M L Terrin
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

Review 2.  Coagulability in obstructive sleep apnea.

Authors:  Christina Liak; M Fitzpatrick
Journal:  Can Respir J       Date:  2011 Nov-Dec       Impact factor: 2.409

3.  Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes.

Authors:  J Hartweg; A J Farmer; R R Holman; H A W Neil
Journal:  Diabetologia       Date:  2006-11-21       Impact factor: 10.122

4.  Human F7 sequence is split into three deep clades that are related to FVII plasma levels.

Authors:  Maria Sabater-Lleal; José Manuel Soria; Jaume Bertranpetit; Laura Almasy; John Blangero; Jordi Fontcuberta; Francesc Calafell
Journal:  Hum Genet       Date:  2005-11-16       Impact factor: 4.132

5.  A gene-centric association scan for Coagulation Factor VII levels in European and African Americans: the Candidate Gene Association Resource (CARe) Consortium.

Authors:  Kira C Taylor; Leslie A Lange; Delilah Zabaneh; Ethan Lange; Brendan J Keating; Weihong Tang; Nicholas L Smith; Joseph A Delaney; Meena Kumari; Aroon Hingorani; Kari E North; Mika Kivimaki; Russell P Tracy; Christopher J O'Donnell; Aaron R Folsom; David Green; Steve E Humphries; Alexander P Reiner
Journal:  Hum Mol Genet       Date:  2011-06-15       Impact factor: 6.150

6.  Association of ACE and FACTOR VII gene variability with the risk of coronary heart disease in north Indian population.

Authors:  R C Sobti; Nishi Maithil; Hitender Thakur; Yashpaul Sharma; K K Talwar
Journal:  Mol Cell Biochem       Date:  2010-04-03       Impact factor: 3.396

7.  Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men.

Authors:  G Ken-Dror; F Drenos; S E Humphries; P J Talmud; A D Hingorani; M Kivimäki; M Kumari; K A Bauer; J H Morrissey; H A Ireland
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

8.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.

Authors:  Cihangir Erem; Ozge Ucuncu; Mustafa Yilmaz; Mustafa Kocak; Irfan Nuhoglu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-10-29       Impact factor: 3.633

9.  Genotype-phenotype relationship of F7 R353Q polymorphism and plasma factor VII coagulant activity in Asian Indian families predisposed to coronary artery disease.

Authors:  Jayashree Shanker; Ganapathy Perumal; Arindam Maitra; Veena S Rao; B K Natesha; Shibu John; Sridhar Hebbagodi; Vijay V Kakkar
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

10.  Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk.

Authors:  N C Olson; L M Raffield; L A Lange; E M Lange; W T Longstreth; G Chauhan; S Debette; S Seshadri; A P Reiner; R P Tracy
Journal:  J Thromb Haemost       Date:  2017-12-08       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.